Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.

A team of US researchers has identified a genetic mutation that increased the risk of humans getting cancer, paving the way ...

The programmed cell death protein 1 (PD-1) inhibitor drug sintilimab in combination with the standard chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) shows significant benefit ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

Fat isn’t just a guilty pleasure — it’s cancer’s secret weapon. New research from UT Southwestern Medical Center is shedding light on why this is the case.

Fat isn't just a guilty pleasure -- it's cancer's secret weapon. New research from UT Southwestern Medical Center is shedding light on why this is the case.